Natera's Landmark RenaCARE Study Demonstrates Significant Diagnostic And Clinical Utility Of Renasight In Chronic Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
Natera, Inc. (NASDAQ:NTRA) announced the publication of initial results from RenaCARE, a study assessing the impact of genetic testing within the chronic kidney disease (CKD) population. The study found that 20.8% of CKD patients had a positive genetic finding, with 48.8% of these patients receiving a new or reclassified diagnosis and 34% receiving information on disease subtype. The results also showed that 90.7% of positive patients had a change in management, including 32.9% with a change in treatment plan.
November 02, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Natera's RenaCARE study results demonstrate the effectiveness of their Renasight genetic test in diagnosing and treating chronic kidney disease. This could potentially increase the demand for Natera's testing services.
The positive results from the RenaCARE study highlight the effectiveness of Natera's Renasight genetic test in diagnosing and treating chronic kidney disease. This could potentially lead to increased demand for Natera's testing services, positively impacting their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100